Literature DB >> 20347093

Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.

Luca Puccetti, Federica Ciani, Alberto Auteri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20347093     DOI： 10.1016/j.atherosclerosis.2010.02.026

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  30 in total

1.  SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.

Authors:  Paulo Caleb Junior Lima Santos; Ana Carolina Moron Gagliardi; Márcio Hiroshi Miname; Ana Paula Chacra; Raul Dias Santos; Jose Eduardo Krieger; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2011-09-18       Impact factor: 2.953

2.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

Review 3.  Applied pharmacogenomics in cardiovascular medicine.

Authors:  Peter Weeke; Dan M Roden
Journal:  Annu Rev Med       Date:  2013-10-02       Impact factor: 13.739

4.  Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.

Authors:  Jason L Vassy; Sojeong Chun; Sanjay Advani; Sophie A Ludin; Jason G Smith; Elaine C Alligood
Journal:  Clin Pharmacol Ther       Date:  2018-10-18       Impact factor: 6.875

5.  Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis.

Authors:  Qian Xiang; Xiao-Dan Zhang; Guang-Yan Mu; Zhe Wang; Zhi-Yan Liu; Qiu-Fen Xie; Kun Hu; Zhuo Zhang; Ling-Yue Ma; Jie Jiang; Yi-Min Cui
Journal:  Eur J Clin Pharmacol       Date:  2020-11-04       Impact factor: 2.953

6.  The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Authors:  R A Wilke; L B Ramsey; S G Johnson; W D Maxwell; H L McLeod; D Voora; R M Krauss; D M Roden; Q Feng; R M Cooper-Dehoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2012-05-23       Impact factor: 6.875

7.  SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.

Authors:  Ju-E Liu; Xiao-Ying Liu; Sheng Chen; Yan Zhang; Li-Yun Cai; Min Yang; Wei-Hua Lai; Bin Ren; Shi-Long Zhong
Journal:  Eur J Clin Pharmacol       Date:  2017-08-15       Impact factor: 2.953

Review 8.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

9.  SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.

Authors:  Josephine H Li; Sunil Suchindran; Svati H Shah; William E Kraus; Geoffrey S Ginsburg; Deepak Voora
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

Review 10.  Cardiovascular Pharmacogenomics--Implications for Patients With CKD.

Authors:  Larisa H Cavallari; Darius L Mason
Journal:  Adv Chronic Kidney Dis       Date:  2016-03       Impact factor: 3.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.